Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 7/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21151866 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| SCHEMBL12437619 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| SCHEMBL29952931 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| SCHEMBL6480162 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| SCHEMBL4040707 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| SCHEMBL6479236 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| Hydrochloric Acid SCHEMBL11149903 | 0.98 | SLC1A2 (0.41) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| Hydrochloric Acid SCHEMBL8385290 | 0.98 | SLC1A2 (0.41) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| Hydrochloric Acid SCHEMBL2157333 | 0.98 | SLC1A2 (0.41) | SLC1A2SLC1A1PKMBLMCYP2D6 | |
| Hydrochloric Acid SCHEMBL19064846 | 0.98 | SLC1A2 (0.41) | SLC1A2SLC1A1PKMBLMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252824-B2 | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | SANOFI (FR) | 2012-08-28 | — | — | US | claimed |
| EP-2212283-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-08-04 | — | — | EP | claimed |
| US-20100173949-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | claimed |
| WO-2009052062-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | claimed |
| US-20060270606-A1 | Dolastatin 15 derivatives | ABBOTT GMBH & CO., KG (DE) | 2006-11-30 | — | — | US | claimed |
| US-7084110-B2 | Anticarcinogenic agents for treating cancer; pentapeptides, hexapeptides, heptapeptides, oligopeptides | ABBOTT GMBH & CO., KG (DE) | 2006-08-01 | — | — | US | claimed |
| EP-0991658-B1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO KG (DE) | 2005-12-28 | — | — | EP | claimed |
| US-20030153505-A1 | Dolastatin 15 derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-14 | — | — | US | claimed |
| US-20010018422-A1 | Dolastatin 15 derivatives | BASF AKTIENGESELLSCHAFT | 2001-08-30 | — | — | US | claimed |
| EP-0804478-B1 | GROWTH FACTOR ANALOGS | SECR DEFENCE (GB) | 2001-03-14 | — | — | EP | claimed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | claimed |
| US-5985837-A | CELL GROWTH INHIBITOR PEPTIDES; TREATING CANCER IN A MAMMAL | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-16 | — | — | US | claimed |
| US-5969099-A | CYCLIC PEPTIDE HAVING MITOGENIC AND AGONIST/ANTAGONIST ACTIVITY FOR EPIDERMAL GROWTH FACTOR RECEPTOR; CONTAINS BICYCLIC PROLINE ANALOG FOR CONSTRAINING PEPTIDE INTO SPECIFIC CONFIGURATION | THE SECRETARY OF STATE FOR DEFENCE (GB) | 1999-10-19 | — | — | US | claimed |
| EP-0804478-A1 | GROWTH FACTOR ANALOGS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 1997-11-05 | — | — | EP | claimed |
| WO-1996021676-A1 | GROWTH FACTOR ANALOGS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 1996-07-18 | — | — | WO | claimed |
| EP-0125106-B1 | 1-ACYLAMINO-1-CYCLOPENTANECARBOXYLIC ACIDS AND A PROCESS FOR PREPARING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1986-09-17 | — | — | EP | claimed |
| US-4405787-A | 3-Carboxy-2-azabicyclo[2.2.1]heptane derivatives | SMITHKLINE BECKMAN CORPORATION (US) | 1983-09-20 | — | — | US | claimed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-4405787-A | 3-Carboxy-2-azabicyclo[2.2.1]heptane derivatives | SMITHKLINE BECKMAN CORPORATION (US) | 1983-09-20 | — | — | US | disclosed |
| US-4405787-A | 3-Carboxy-2-azabicyclo[2.2.1]heptane derivatives | SMITHKLINE BECKMAN CORPORATION (US) | 1983-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018422-A1 | Dolastatin 15 derivatives | SLCO2B1, SLCO2A1, DDOST | SLC1A2 1147/4885SLC1A1 829/4885PKM 2801/4885 |
| US-20100173949-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | SLC1A2 197/4885SLC1A1 216/4885PKM 1531/4885 |
| US-20030153505-A1 | Dolastatin 15 derivatives | DBI, DDOST, BDKRB1 | SLC1A2 2264/4885SLC1A1 1382/4885PKM 1820/4885 |
| US-20060270606-A1 | Dolastatin 15 derivatives | DDOST, DBI, DAO | SLC1A2 2314/4885SLC1A1 1507/4885PKM 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.